Discontinue fezolinetant if transaminase elevations are > 5 × the upper limit of normal (ULN) or transaminase elevations are > 3 × ULN and total bilirubin is > 2 × ULN, or if patients experience signs or symptoms that may suggest liver injury
VEOZAH [package insert]. Northbrook, IL, USA: Astellas Pharma, Inc. Available at: https://www.astellas.com/us/system/files/veozah_uspi.pdf.
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here